Lytix Biopharma AS (FRA:6BG)

Lytix Biopharma AS Cash Flow Statement

Financials in millions NOK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-59.98	-94.27	-87.9	-56.07	-48.08
Depreciation & Amortization	1	0.92	0.96	0.92	0.45
Stock-Based Compensation	13.84	0.88	4.18	1.38	4.05
Other Operating Activities	-2.32	-1.5	-2.35	-1.35	-0.13
Change in Accounts Receivable	6.03	-0.34	-6.04	-1.06	-1.51
Change in Accounts Payable	-18.43	23.94	-4.83	3.55	0.61
Operating Cash Flow	-59.85	-70.37	-95.97	-52.63	-44.61
Capital Expenditures	-	-	-0.05	-0.15	-
Investment in Securities	-61.76	23.18	27.42	-50.61	-
Other Investing Activities	2.33	1.51	2.35	1.41	0.14
Investing Cash Flow	-59.43	24.69	29.73	-49.36	0.14
Long-Term Debt Repaid	-0.9	-0.85	-0.94	-0.83	-0.42
Net Debt Issued (Repaid)	-0.9	-0.85	-0.94	-0.83	-0.42
Issuance of Common Stock	-	161.3	-	0.13	225.21
Other Financing Activities	-0.01	-11.34	-0	-0.06	-11.49
Financing Cash Flow	-0.91	149.11	-0.94	-0.75	213.3
Miscellaneous Cash Flow Adjustments	0	-	-	-	-0
Net Cash Flow	-120.19	103.43	-67.19	-102.73	168.83
Free Cash Flow	-59.85	-70.37	-96.02	-52.78	-44.61
Free Cash Flow Margin	-	-632.05%	-2405.86%	-478.47%	-231.04%
Free Cash Flow Per Share	-0.88	-1.30	-2.40	-1.33	-1.34
Cash Interest Paid	0.01	0.01	0	0.06	0
Levered Free Cash Flow	-37.7	-34.62	-66.3	-36.49	-26.43
Unlevered Free Cash Flow	-37.57	-34.54	-66.27	-36.4	-26.39
Change in Working Capital	-12.39	23.6	-10.87	2.5	-0.9

Source: S&P Global Market Intelligence. Standard template. Financial Sources.